Comparison of tolterodine, trospium chloride, solifenacin treatments and its side effects on patients with pure urinary and mixed incontinence

Yıl 2022, Cilt: 5 Sayı: 5, 1207 - 1214, 25.09.2022

İzzet Özgürlük , Eylem Ünlübilgin , İsmail Dölen

https://doi.org/10.32322/jhsm.1106031

Öz

Objective: Urinary incontinence is defined as urinary incontinence that is a social or hygienic problem and can be objectively demonstrated. It is aimed to compare tolterodine, trospium chloride and solifenacin treatments, and its side effects on patients who have complaints of pure urinary and mixed incontinence.
Material and Method: Totally 98 patients, who applied to Ankara Etlik Zubeyde Hanım Gynecology Training and Research Hospital, Urogynecology Outpatient Clinic between November 2009 and October 2010 with compliants of urinary incontinence and met the criteria to participate in the research, have been included in this study.
Results: A significant improvement in each three of the drug group at third and six months was determined. Solifenacin is generally more effective than the other two treatments. When total values of UDI-6 (Urinary Distress Inventory) survey is analysed, it is seen that each of three antimuscarinic drug group ensured improvement on symptoms at the end of the third month as not to be different from the improvement at the six month. Each three antimuscarinic drug group has a significant therapeutic effect on the IIQ-7 (Incontinence Impact Questionnaire) survey which questions the life quality. Whereas complaints of constipation was seen more at patients that use tolterodine and trospium chloride, there was not a significant difference despite a slight increase in the solifenacin group (p>0.05). It is determined that solifenacin caused desert mouth less than the other two drug groups
Conclusion: Tolterodine, trospium chloride and solifenacin as anticholinergic drugs meaningfully reduced the activity of bladder and increased the quality of life. Drug therapy provided an effective and efficient improvement on incontinence.

Anahtar Kelimeler

Pure urinary incontinence, tolterodine, trospium chloride, solifenacin, urogenital distress inventory, incontinence impact questionnaire

Kaynakça

• Abrams P, Blaivas JG, Stanton SL, et al. The standardisation of terminology of lower urinary tract function. Scand J Urol Nephrol 1988; 114: 5–18.
• Imamura M, Abrams P, Bain C, et al. Systematic review and economic modelling of the effectiveness and cost-effectiveness of non-surgical treatments for women with stress urinary incontinence. Health Technol Assess 2010; 14: 1-188.
• Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein A. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalance study. Br J Urol Int 2001; 87: 760-6.
• Stewart WF, Corey R, Herzog AR, et al. Prevalance overactive bladder in women: results from the Noble Program. Int Urogynecol J Pelvic Floor Dysfunct 2001; 12: 66.
• Mills IW, Greenland JE, McMurray G, et al. Studies of the pathophysiology of idiopathic detrusor instability: the physiological properties of the detrusor smooth muscle and its pattern of innervation. J Urol 2000; 163: 646–51.
• Ghoniem GM, Walters F, Levis V. The value of vaginal pack test in large cyctoceles. J Urol 1994; 152: 931-4.
• Wall LL. Diagnosis and management of urinary incontinence due to detrusor instability. Obstet Gynecol Surv 1990; 45: 1–47.
• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the stadardisation sub-comittee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78.
• Michel MC, de la Rosette JJ, Piro M, et al. Comparison of symtom severity and treatment response in patients with incontinent and overactive bladder. Eur Urol 2005; 48: 110-5.
• Herbison P, Hay Smith J, Ellis G, Moore K. Effectiveness of anticholinerjic drugs compared with placebo in the treatment of overactive bladder: systematic review. Br Med J 2003; 326: 841-4.
• Scheife R, Pharm D, FCCP; Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Therap 2005; 27: 144-53.
• Michel MC, Oelke M, Zinner N. Novel muscarinic antagonists to treat incontinence and overactive. Drug Discovery Today 2005: 1-6
• Kristen Hesch. Agents for treatment of overactive bladder: a therapeutic class review. Proc (Bayl Univ Med Cent) 2007; 20: 307-14.
• Hay-Smith J, Herbison P, Ellis G, Moore K. Anticholinerjic drugs versus plasebo for overactve bladder syndrome in adults. Cochrane Database Syst Rew 2002: 3.
• Chapple CR, Arano P, Bosch JL, et al. Solifenacin appears effective and well tolerated in patients with symtomatic idiopathic detrusor overactive in a plasebo and tolterodine controlled phase 2 dose-finding study. BJU Int 2004; 93: 71-7.
• Haeusler G, Letitch H, Van Trotsenberg M, et al. Drug therapy of urinary urge incontinence. Obstet Gynecol 2002; 100: 1003-16.
• Drutz H, Appell RA, Gleason D, Klimberg I, Randomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and plasebo in patients with overactive bladder. Int urogynecol J Pelvic Floor Dysfunc 1999; 10: 283-9.
• Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new muscarinic agent: as effective but better than oxybutynin and plasebo in patients with an overactive bladder. Br J Urol 1998; 81: 801-10.
• Anderson KE, Appell R, Cardozo LD, et al. The pharmacological treatment of urinary incontinence. BJU Int 1999; 84: 923-47.
• Van Kerrebroeck PEVA, Serment G, Dreher E. Clinical efficacy and safety of olterodine compared to oxybutynin in patients with overactive bladder. Neurourol Urodyn 1997; 16: 478-9.
• Burgio K, Matthews KA, Engel BT. Prevalence, incidence and correlates of urinary incontinence in healthy, middle-aged women. J Urol 1991; 146: 1255-9.
• Diokno AC, Brock BM, Brown MB et al. Prevelance of urınery incontinance and other urological symtoms in the noninstituinalized elderly. J Urol 1986; 136: 1022-6.
• Dwyer PL, Lee ETC, Hay DM. Obesity and urinary incontinence in women. Br J Obstet Gynecol 1988; 95: 91-4.
• Bump RC, Sugarman HJ, Fanti JA, McCiish DK. Obesity and lower urinary tract function in women. Efect of surgically induced vveight loss. Am J Obstet Gynecol 2002; 167: 392-7.
• Parazzini F, Colli E, Origgi G, et al. Risk factors for urinary incontinence in women. Eur Urol 2000; 37: 637-43.
• Cam C, Sakalli M, Ay P, Cam M, Karateke A. Validation of the short forms of the incontinence impact questionnaire (IIQ-7) and the urogenital distress inventory (UDI-6) in a Turkish population. Neurourology and Urodynamics 2007; 26: 129-33.
• Abrams P, Swift S. Solifenasin is Effective for the treatment of OAB dry patients: a pooled analysis. Eur Urol 2005; 48: 483-7.
• Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 464-70.
• Chapple CR, Fianu Jonsson A, Indig M, et al. STAR study group Treatment outcomes in the STAR study: a subanalysis of 5mg and tolterodine ER 4mg. Eur Urol 2007; 52: 1195-203.
• Herbison P, Hay Smith J, Ellis G, Moore K. Effectiveness of anticholinerjic drugs compared with plasebo in the treatment of overactive bladder: systematic review. Br Med J 2003; 326: 841-4.
• Lauti M, Hay-Smith J, Herbison P, et al. Anticholinergic drugs, bladder retraining and their combination for urge urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19: 1533-43.
• Rovner ES. Trospium chloride in the management of overactive bladder. Drugs 2004; 64: 2433-46.
• Hesch K. Agents for treatment of overactive bladder: a therapeutic class review. Bayl Univ Med Cent Proceedings 2007; 20: 307-14.
• Herbison P, Hay Smith J, Ellis G, Moore K. Effectiveness of anticholinerjic drugs compared with plasebo in the treatment of overactive bladder: systematic review. Br Med J 2003; 326: 841-4.
• Metello J, Nogueira B, Torgal M, et al. Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride. Int Urogynecol J 2007; 18: 1021-5.
• Kessler TM, Bachmann LM, Minder C, et al. Adverse event assessment of antimuscarinics for treating overactive bladder. PloS One 2011; 6: 167-8.